Skip to content

Mail Outreach To Increase Vaccination Acceptance Through Engagement

Mail Outreach To Increase Vaccination Acceptance Through Engagement

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02243774
Acronym
MOTIVATE
Enrollment
228000
Registered
2014-09-18
Start date
2014-09-30
Completion date
2015-09-30
Last updated
2017-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Flu, Influenza, Influenza, Human

Keywords

Vaccination, Immunization, Randomized Controlled Trial, Prevention & Control, Preventive Measures, Health Promotion, Medicare, Intention Prompts, Letters

Brief summary

The aim of this study is to determine whether receiving a core letter signed by the Surgeon General or the Director of the National Vaccine Program that provides only information about influenza, or a core letter signed by the Surgeon General with an added basic or enhanced implementation prompt, will increase rates of influenza vaccination among Medicare beneficiaries when compared to a control group.

Interventions

BEHAVIORALCore letter signed by Surgeon General

The core letter provides information about influenza and the risks associated with it, incorporating a number of behavioral insights. All four letters evaluated in this study will contain the same tops and bodies that are included in the core letter, but the signature and P.S. tag region will differ among the various intervention groups. In this intervention, the core letter is signed by and includes a picture of the Surgeon General. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.

BEHAVIORALCore letter signed by the Director of the National Vaccine Program

The core letter is signed by and includes a picture of the Director of the National Vaccine Program. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.

BEHAVIORALCore letter signed by Surgeon General + implementation prompt

The core letter is signed by and includes a picture of the Surgeon General. Below the signature line of the core letter, an implementation intention prompt is provided in the P.S. tag region that invites the recipient to write in the day of week, month, day, and time at which he or she plans to get vaccinated.

BEHAVIORALCore letter signed by SG + enhanced implementation prompt

The core letter is signed by and includes a picture of the Surgeon General (SG). Below the signature line of the core letter, an enhanced implementation intention prompt is provided in the P.S. tag region that prompts recipients to decide now - by checking one of two boxes - indicating they will or will not get vaccinated. The options use language that highlights the losses incumbent in refusing to vaccinate. In addition, an implementation intention prompt is embedded into the checkbox for indicating a choice to be vaccinated.

Sponsors

Department of Health and Human Services
CollaboratorFED
Centers for Medicare and Medicaid Services
CollaboratorFED
United States Social and Behavioral Sciences Team
CollaboratorUNKNOWN
Brigham and Women's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
66 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Medicare fee-for-service beneficiaries aged 66 and older are eligible for study inclusion. There will be no additional

Exclusion criteria

.

Design outcomes

Primary

MeasureTime frameDescription
Number of study participants who receive influenza vaccination4 monthsPrimary outcome of interest, determined from administrative claims data, will be the number of beneficiaries in each experimental group who receive an influenza vaccination between the date letter is mailed in September 2014 and January 31, 2015

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026